CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Get practical Zero Based Budgeting insights that help you refine your dollar allocations and boost financial efficiency.
16,266 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Chewy’s stock action in May left investors asking what happened and what comes next. This article breaks down the cat...
A broad coalition urges the Senate to take up the CLARITY Act, intensifying the fight over crypto regulation even as ...
The Social Security Administration’s new commissioner argues that wait times are down and more people are being serve...
Anchor Real Estate, led by Kelli Salter, secures a top-20 finish in RealTrends 2026 The Thousand, highlighting its sp...
As a pivotal inflation reading nears, investors brace for the potential shock. This article explains why wall street'...
Memory changes in seniors may come from a reversible vitamin issue rather than dementia. Doctors say B12 deficiency c...
A new release from Anthropic is triggering a global debate over hidden safeguards. Critics say Claude Fable 5 quietly...
The Joe McNally Team of REMAX Together in Big Rapids, Michigan, lands No. 28 among small teams in RealTrends Verified...
OpenAI signals pricing tilt as competition heats up. New usage data shows AI demand cooling, pushing executives to co...
SpaceX is set to debut on the public market tomorrow after planning a record-breaking raise, drawing unprecedented in...
SpaceX's IPO hype is hard to ignore, but there are four solid concerns investors should weigh before buying in. This ...